

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 2

C. <i>Complete if Known</i>	
Application Number	Unassigned
Filing Date	January 16, 2002
First Named Inventor	William J. Robert
Group Art Unit	Unassigned
Examiner Name	Unassigned

C903 U.S. 970



## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

**Examiner  
Signature**

Sabine Ozys

**Date Considered**

5/28/03

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

*Complete if Known*

Application Number	Unassigned
Filing Date	January 16, 2002
First Named Inventor	William J. Roberts
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number

1400-004

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BLAQUIER et al., "In Vitro Metabolism of Androgens in Whole Human Blood", Acta Endocrinologica, May-August 1967, 697-704, Vol. 55, Periodica, Copenhagen.	
		EARNEST et al., "In Vivo 4-androstene-3,17-dione and 4-androstene-3 $\beta$ ,17 $\beta$ -diol Supplementation in Young Men", European Journal of Applied Physiology, February 2000, 229-232, Vol. 81, No. 3, Springer, New York.	
		FRANKE et al., "Hormonal Doping and Androgenization of Athletes: A Secret Program of the German Democratic Republic Government", Clinical Chemistry, Nov. 7, 1997, 1262-1279, Vol. 43, No. 7, American Association for Clinical Chemistry, United States of America.	
SAB		INABA et al., "Conversion of 4-Androstenediol and 5-Androstenediol to Testosterone, and Conversion of Dehydroepiandrosterone to 4-Androstenediol by Rat Testis In Vitro", Endocrinol. June 1966, 160-172, Vol. 13, No. 2, Japan.	
		URALETS et al., "Over-the-Counter Anabolic Steroids 4-Androsten-3, 17-dione; 4-Androsten-3 $\beta$ ,17 $\beta$ -diol; and 19-nor-4-Androsten-3, 17-dione: Excretion Studies in Men", Journal of Analytical Toxicology, September 1999, 357-366, Vol. 23, : Preston Publications, Niles, Illinois.	
		YAMAJI et al., "Androstenediol in Canine Spermatic Vein Blood and Its Significance in Testosterone Biosynthesis in Vivo", Endocrinology, 1968, 992-998, Vol. 83, J. B. Lippincott, Philadelphia.	

Examiner Signature

*Sabika Qazi*

Date Considered

5/28/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

